Key Financial Data Of Group

SymBio Pharmaceuticals Limited - Filing #7272884

Concept	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	As at 2024-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31
Key financial data of group
Business results of group
Net sales	—	2,452,912,000 JPY	2,452,912,000 JPY	—	—	5,589,708,000 JPY	—	5,589,708,000 JPY	—	—	10,008,338,000 JPY	—	10,008,338,000 JPY	8,256,924,000 JPY	—	—	JPY	JPY	—	2,987,051,000 JPY	—
Ordinary profit (loss)	—	-3,802,316,000 JPY	-3,689,435,000 JPY	—	—	-736,130,000 JPY	—	-773,822,000 JPY	—	—	1,999,878,000 JPY	—	2,001,204,000 JPY	1,001,133,000 JPY	—	—	JPY	JPY	—	-4,615,903,000 JPY	—
Profit (loss) attributable to owners of parent	—	—	-3,833,480,000 JPY	—	—	-1,962,817,000 JPY	—	—	—	—	1,179,238,000 JPY	—	—	—	—	—	JPY	JPY	—	—	—
Comprehensive income	—	—	-3,819,600,000 JPY	—	—	-1,956,588,000 JPY	—	—	—	—	1,179,437,000 JPY	—	—	—	—	—	JPY	JPY	—	—	—
Net assets	4,080,779,000 JPY	—	—	—	4,197,560,000 JPY	—	7,209,909,000 JPY	—	7,197,165,000 JPY	8,506,092,000 JPY	—	8,511,025,000 JPY	—	—	6,745,672,000 JPY	JPY	—	—	4,657,318,000 JPY	—	JPY
Total assets	4,719,369,000 JPY	—	—	—	4,968,333,000 JPY	—	8,170,243,000 JPY	—	8,177,010,000 JPY	10,433,347,000 JPY	—	10,410,354,000 JPY	—	—	8,452,997,000 JPY	JPY	—	—	6,274,707,000 JPY	—	JPY
Net assets per share	82.12	—	—	—	84.66	—	164.32	—	164.02	204.83	—	204.95	—	—	162.26		—	—	105.76	—
Basic earnings (loss) per share	—	-87.00	-85.00	—	—	-49.19	—	-49.79	—	—	30.20	—	30.37	53.04	—	—			—	-124.13	—
Diluted earnings per share	—			—	—		—		—	—	29.77	—	29.95	52.32	—	—			—		—
Equity-to-asset ratio	0.797 xbrli:pure	—	—	—	0.781 xbrli:pure	—	0.849 xbrli:pure	—	0.846 xbrli:pure	0.776 xbrli:pure	—	0.778 xbrli:pure	—	—	0.737 xbrli:pure	xbrli:pure	—	—	0.643 xbrli:pure	—	xbrli:pure
Rate of return on equity	—	xbrli:pure	xbrli:pure	—	—	xbrli:pure	—	xbrli:pure	—	—	0.146 xbrli:pure	—	0.166 xbrli:pure	0.396 xbrli:pure	—	—	xbrli:pure	xbrli:pure	—	xbrli:pure	—
Price-earnings ratio	—	xbrli:pure	xbrli:pure	—	—	xbrli:pure	—	xbrli:pure	—	—	21.3 xbrli:pure	—	21.2 xbrli:pure	21.6 xbrli:pure	—	—	xbrli:pure	xbrli:pure	—	xbrli:pure	—
Net cash provided by (used in) operating activities	—	JPY	-3,416,518,000 JPY	—	—	-194,685,000 JPY	—	JPY	—	—	1,614,241,000 JPY	—	JPY	140,042,000 JPY	—	—	JPY	JPY	—	-4,122,483,000 JPY	—
Net cash provided by (used in) investing activities	—	JPY	-3,955,000 JPY	—	—	-376,696,000 JPY	—	JPY	—	—	-47,127,000 JPY	—	JPY	-70,849,000 JPY	—	—	JPY	JPY	—	-160,309,000 JPY	—
Net cash provided by (used in) financing activities	—	JPY	708,472,000 JPY	—	—	680,160,000 JPY	—	JPY	—	—	627,985,000 JPY	—	JPY	-71,922,000 JPY	—	—	JPY	JPY	—	4,222,090,000 JPY	—
Cash and cash equivalents	JPY	—	—	—	3,963,580,000 JPY	—	6,517,007,000 JPY	—	JPY	6,282,554,000 JPY	—	JPY	—	—	3,860,106,000 JPY	JPY	—	—	3,848,626,000 JPY	—	JPY
Number of employees	101 xbrli:pure	—	—	108 xbrli:pure	108 xbrli:pure	—	109 xbrli:pure	—	103 xbrli:pure	122 xbrli:pure	—	118 xbrli:pure	—	—	141 xbrli:pure	xbrli:pure	—	—	127 xbrli:pure	—	xbrli:pure
Average number of temporary employees	15 xbrli:pure	—	—	15 xbrli:pure	15 xbrli:pure	—	20 xbrli:pure	—	20 xbrli:pure	30 xbrli:pure	—	28 xbrli:pure	—	—	45 xbrli:pure	xbrli:pure	—	—	41 xbrli:pure	—	xbrli:pure